» Articles » PMID: 23350049

Comparison of Gastroesophageal Reflux Disease Symptoms and Proton Pump Inhibitor Response Using Gastroesophageal Reflux Disease Impact Scale Questionnaire

Overview
Date 2013 Jan 26
PMID 23350049
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: To compare gastroesophageal reflux disease (GERD) symptoms and response to proton pump inhibitor (PPI) in patients with erosive esophagitis (EE), non-erosive reflux disease (NERD) or functional heartburn (FH) using GERD impact scale (GIS) questionnaire.

Methods: Total 126 patients with GERD symptoms were diagnosed as EE (n = 62), NERD (n = 34) and FH (n = 30) by endoscopy, 24-hour esophageal pH testing and Bernstein test, prospectively. Analysis of risk factors and GIS questionnaire for GERD symptoms and quality of life were performed before and 8 weeks after PPI treatment.

Results: EE group had a higher proportion of men, frequent alcohol consumption, smoking, hiatal hernia, body mass index ≥ 25 kg/m(2) and triglyceride levels (≥ 150 mg/dL) than the other groups (all P < 0.05). On the other hand, both psychiatric treatment and psychopharmacotherapy were more frequent in patients with FH than in those with EE and NERD (both P < 0.05). Among GERD symptoms, chest pain was more frequent in FH group than in EE and NERD groups (P < 0.05). Eating problems and limitation of productive daily activities occurred frequently in FH group and NERD group, respectively. GIS after 8 week PPI treatment showed improvement in all of the GERD symptoms in EE (all P < 0.05) and in acid regurgitation, epigastric pain and hoarseness in NERD group (all P < 0.05). In terms of quality of life, PPI treatment improved sleep disturbance in EE (P = 0.031) and limitation of productive activity in the NERD group (P = 0.001).

Conclusions: GIS questionnaire showed that different characteristics and symptoms improved after PPI therapy among patients with EE, NERD and FH, demonstrating the usefulness of the GIS questionnaire.

Citing Articles

Exacerbation of symptoms, nocturnal acid reflux, and impaired autonomic function are associated with sleep disturbance in gastroesophageal reflux disease patients.

Huang Y, Liu J, Xu L, Qi W, Dai J, Wang B Front Med (Lausanne). 2024; 11:1438698.

PMID: 39234038 PMC: 11371777. DOI: 10.3389/fmed.2024.1438698.


Risk factors and 26-years worldwide prevalence of endoscopic erosive esophagitis from 1997 to 2022: a meta-analysis.

Witarto A, Witarto B, Pramudito S, Ratri L, Wairooy N, Konstantin T Sci Rep. 2023; 13(1):15249.

PMID: 37709957 PMC: 10502104. DOI: 10.1038/s41598-023-42636-7.


Long-Term Outcomes of Chronic Cough Reduction after Laparoscopic Nissen Fundoplication-A Single-Center Study.

Dowgiallo-Gornowicz N, Masiewicz A, Kacperczyk J, Lech P, Saluk S, Osowiecka K Medicina (Kaunas). 2022; 58(1).

PMID: 35056354 PMC: 8779940. DOI: 10.3390/medicina58010047.


Comparison of Tight Junction Protein-Related Gene mRNA Expression Levels between Male and Female Gastroesophageal Reflux Disease Patients.

Kim J, Kim N, Park J, Kim Y, Lee S, Lee D Gut Liver. 2018; 12(4):411-419.

PMID: 29558791 PMC: 6027836. DOI: 10.5009/gnl17419.


Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease.

Ranaldo N, Losurdo G, Iannone A, Principi M, Barone M, De Carne M Cell Death Dis. 2017; 8(9):e3040.

PMID: 28880273 PMC: 5636981. DOI: 10.1038/cddis.2017.436.


References
1.
Trimble K, PRYDE A, Heading R . Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut. 1995; 37(1):7-12. PMC: 1382759. DOI: 10.1136/gut.37.1.7. View

2.
Wong W, Lai K, Lam K, Hui W, Huang J, Xia H . Onset and disappearance of reflux symptoms in a Chinese population: a 1-year follow-up study. Aliment Pharmacol Ther. 2004; 20(7):803-12. DOI: 10.1111/j.1365-2036.2004.02198.x. View

3.
Sarnelli G, De Giorgi F, Efficie E, Aprea G, Masone S, Savarese M . Correlation between oesophageal acid exposure and dyspeptic symptoms in patients with nonerosive reflux disease. Eur J Gastroenterol Hepatol. 2008; 20(4):264-8. DOI: 10.1097/MEG.0b013e3282f340b2. View

4.
Collen M, Abdulian J, Chen Y . Gastroesophageal reflux disease in the elderly: more severe disease that requires aggressive therapy. Am J Gastroenterol. 1995; 90(7):1053-7. View

5.
Talley N, Meineche-Schmidt V, Pare P, Duckworth M, Raisanen P, Pap A . Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther. 1998; 12(11):1055-65. DOI: 10.1046/j.1365-2036.1998.00410.x. View